Immuneering Co. (NASDAQ:IMRX) Major Shareholder Cormorant Asset Management, Lp Sells 400,000 Shares of Stock

Immuneering Co. (NASDAQ:IMRXGet Free Report) major shareholder Cormorant Asset Management, Lp sold 400,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $2.90, for a total value of $1,160,000.00. Following the completion of the sale, the insider now owns 2,895,273 shares of the company’s stock, valued at approximately $8,396,291.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Cormorant Asset Management, Lp also recently made the following trade(s):

  • On Thursday, March 14th, Cormorant Asset Management, Lp sold 509,091 shares of Immuneering stock. The stock was sold at an average price of $3.72, for a total transaction of $1,893,818.52.

Immuneering Trading Down 4.0 %

Shares of NASDAQ IMRX opened at $2.40 on Thursday. Immuneering Co. has a 1 year low of $1.90 and a 1 year high of $14.29. The company’s 50-day moving average is $5.16 and its 200 day moving average is $6.19.

Immuneering (NASDAQ:IMRXGet Free Report) last posted its earnings results on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.06). On average, research analysts anticipate that Immuneering Co. will post -1.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Immuneering

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Immuneering by 2.9% during the fourth quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company’s stock valued at $7,893,000 after buying an additional 29,963 shares during the period. Virtu Financial LLC purchased a new position in Immuneering during the 4th quarter valued at about $84,000. Barclays PLC boosted its stake in Immuneering by 327.0% during the fourth quarter. Barclays PLC now owns 34,923 shares of the company’s stock worth $257,000 after acquiring an additional 26,744 shares in the last quarter. Nuveen Asset Management LLC increased its stake in shares of Immuneering by 8.6% during the fourth quarter. Nuveen Asset Management LLC now owns 44,049 shares of the company’s stock valued at $324,000 after purchasing an additional 3,504 shares in the last quarter. Finally, Oracle Alpha Inc. purchased a new position in shares of Immuneering during the fourth quarter valued at approximately $87,000. 67.65% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on IMRX shares. Guggenheim reissued a “neutral” rating on shares of Immuneering in a report on Thursday, March 14th. Oppenheimer reissued an “outperform” rating and issued a $25.00 target price on shares of Immuneering in a research note on Tuesday, March 5th. Mizuho lowered their price target on Immuneering from $20.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday. Chardan Capital dropped their price objective on Immuneering from $21.00 to $16.00 and set a “buy” rating for the company in a report on Friday, March 15th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $3.00 target price (down from $16.00) on shares of Immuneering in a research note on Friday, March 15th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Check Out Our Latest Research Report on IMRX

About Immuneering

(Get Free Report)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

Further Reading

Insider Buying and Selling by Quarter for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.